Ovarian Cancer Biomarkers - Mapping to Improve Outcomes

Ovarian Cancer Biomarkers - Mapping to Improve Outcomes

von: Khalid El Bairi

Springer-Verlag, 2021

ISBN: 9789811618734 , 229 Seiten

Format: PDF

Kopierschutz: Wasserzeichen

Windows PC,Mac OSX für alle DRM-fähigen eReader Apple iPad, Android Tablet PC's

Preis: 106,99 EUR

Mehr zum Inhalt

Ovarian Cancer Biomarkers - Mapping to Improve Outcomes


 

This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.

Khalid El Bairi is the founder of The Cancer Biomarkers Working Group, and he is currently pursuing clinical and translational research in medical oncology. He has published many peer-reviewed articles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of the board of various international scientific societies such as the International Gynecologic Cancer Society (IGCS), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for more than 40 journals, including BMC Cancer, PLoS ONE and Frontiers in Oncology, and a guest editor for several special issues on gynecological cancers, including Seminars in Cancer Biology and Current Drug Targets. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and Ph.D. students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist.